drugset / Trial / NCT04064411

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

NCT04064411

Phase 3 Completed 511 enrolled Radius Health, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

A 12-month study to compare the efficacy and safety of abaloparatide-solid microstructured transdermal system (sMTS) with abaloparatide-subcutaneous (SC).

Timeline

Start
2019-08-05
Primary completion
2021-10-05
Completion
2021-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Abaloparatide Peptide 80 ug Subcutaneous
Subject Abaloparatide Peptide 300 ug Other